Taysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12
Taysha Gene Therapies (NASDAQ:TSHA), a clinical-stage biotech company specializing in AAV-based gene therapies for CNS diseases, will host its Q2 2025 financial results conference call on August 12, 2025, at 8:30 AM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Taysha Gene Therapies (NASDAQ:TSHA), a clinical-stage biotech company specializing in AAV-based gene therapies for CNS diseases, will host its Q2 2025 financial results conference call on August 12, 2025, at 8:30 AM ET. The company will present its financial performance for the quarter ended June 30, 2025, along with a corporate update.
Investors can access the call via toll-free number (877-407-0792) or international line (201-689-8263) using conference ID 13754869. A webcast will also be available on the company's investor relations website.
Details
News Market Reaction – TSHA
On Aug 6, the first trading day after this news, TSHA closed 1.82% above the previous close.
Data tracked by StockTitan Argus for the Aug 6 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DALLAS, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the second quarter ended June 30, 2025, and host a corporate update conference call and webcast on Tuesday, August 12, 2025, at 8:30 AM Eastern Time.
Conference Call Details
Tuesday, August 12, at 8:30 AM Eastern Time / 7:30 AM Central Time
Toll Free: 877-407-0792
International: 201-689-8263
Conference ID: 13754869
Webcast: https://ir.tayshagtx.com/news-events/events-presentations
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit http://www.tayshagtx.com.
Company Contact:
Hayleigh Collins
Senior Director, Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com
Media Contact:
Carolyn Hawley
Inizio Evoke
carolyn.hawley@inizioevoke.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.